Core Insights - The announcement from Meizhong Jiahe marks a significant milestone for its proton therapy center in Guangzhou, indicating a successful transition from technology introduction to capability realization in the medical sector [2][5] - The healthcare industry in China is undergoing a structural adjustment, shifting from a "scale dividend" model to one focused on "capability premium," emphasizing the importance of specialized assets with high technical barriers [2] Group 1: Company Performance - Meizhong Jiahe has demonstrated its strength as an industry "standard setter," participating in the formulation of six national clinical guidelines and establishing a strong academic foundation in proton therapy [3] - The company has achieved a comprehensive breakthrough in clinical breadth, depth, and operational efficiency, completing a closed loop from "heavy asset investment" to "high-quality output" [3][4] - The proton therapy center has shown significant growth in patient intake, indicating a strong brand influence and operational efficiency, with all four treatment rooms operating at full capacity [4] Group 2: Industry Context - The recent "2025 China Social Medical New Ecology Conference" highlighted the need for sustainable clinical output from high-cost medical equipment, which is a critical measure of the level of social medical services [2] - The center's service range extends across 31 provinces and over 20 countries, showcasing its international reach in high-end medical services, particularly in pediatric proton therapy [4] - The completion of China's first proton treatment for ocular malignant melanoma in July 2025 fills a domestic gap and reinforces the center's position in high-difficulty tumor treatments [4]